Table 5.
Risk for DLBCL and FL by tertiles of circulating markersa
| DLBCL | FL | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| T1 | T2 | T3 | ptrend b | T1 | T2 | T3 | ptrend b | |
|
|
|
|||||||
| Adiponectin, μg/mL | <5.6 | 5.6–<11.0 | ≥11.0 | <5.6 | 5.6–<11.0 | ≥11.0 | ||
| Cases/controls | 28/49 | 24/57 | 27/51 | . | 16/32 | 19/30 | 14/34 | |
| OR (95% CI) all | 1.00 | 0.70 (0.33, 1.45) | 0.85 (0.40, 1.78) | 0.83 | 1.00 | 1.19 (0.52, 2.73) | 0.82 (0.31, 2.20) | 0.80 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.61 (0.27, 1.39) | 0.86 (0.39, 1.92) | 0.84 | 1.00 | 1.06 (0.38, 2.99) | 0.50 (0.14, 1.75) | 0.35 |
| Leptin, ng/ml | <6.4 | 6.4–<14.9 | ≥14.9 | <6.4 | 6.4–<14.9 | ≥14.9 | ||
| Cases/controls | 28/45 | 28/56 | 23/56 | . | 17/21 | 20/34 | 12/41 | |
| OR (95% CI) all | 1.00 | 0.73 (0.36, 1.50) | 0.49 (0.20, 1.24) | 0.33 | 1.00 | 0.49 (0.17, 1.38) | 0.13 (0.03, 0.53) | <0.01 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.96 (0.44, 2.13) | 0.74 (0.27, 2.00) | 0.93 | 1.00 | 0.49 (0.13, 1.78) | 0.16 (0.03, 0.95) | 0.06 |
| IFN-γ, pg/mL | <0.5 | 0.5–<0.9 | ≥0.9 | <0.5 | 0.5–<0.9 | ≥0.9 | ||
| Cases/controls | 24/52 | 26/64 | 29/41 | . | 20/35 | 12/28 | 17/33 | |
| OR (95% CI) all | 1.00 | 0.91 (0.45, 1.82) | 1.60 (0.79, 3.26) | 0.23 | 1.00 | 0.72 (0.28, 1.82) | 0.85 (0.33, 2.16) | 0.93 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.76 (0.36, 1.60) | 1.41 (0.65, 3.06) | 0.64 | 1.00 | 0.53 (0.17, 1.70) | 0.91 (0.31, 2.68) | 0.88 |
| IL-1β, pg/mL | <0.6 | 0.6–<1.6 | ≥1.6 | <0.6 | 0.6–<1.6 | ≥1.6 | ||
| Cases/controls | 23/49 | 24/59 | 32/49 | . | 23/40 | 10/29 | 16/27 | |
| OR (95% CI) all | 1.00 | 0.90 (0.43, 1.87) | 1.48 (0.72, 3.05) | 0.32 | 1.00 | 0.56 (0.21, 1.52) | 0.99 (0.38, 2.56) | 0.07 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.10 (0.50, 2.41) | 1.45 (0.64, 3.28) | 0.78 | 1.00 | 0.97 (0.32, 2.99) | 1.19 (0.39, 3.60) | 0.13 |
| IL-2, pg/mL | <0.9 | 0.9–<1.9 | ≥1.9 | <0.9 | 0.9–<1.9 | ≥1.9 | ||
| Cases/controls | 29/52 | 24/41 | 26/64 | . | 17/39 | 16/29 | 16/28 | |
| OR (95% CI) all | 1.00 | 1.03 (0.49, 2.17) | 0.70 (0.34, 1.41) | 0.54 | 1.00 | 1.31 (0.53, 3.25) | 1.35 (0.53, 3.43) | 0.22 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.92 (0.40, 2.12) | 0.52 (0.23, 1.17) | 0.79 | 1.00 | 1.60 (0.53, 4.82) | 1.25 (0.38, 4.11) | 0.34 |
| IL-4, pg/mL | <1.4 | 1.4–<3.4 | ≥3.4 | <1.4 | 1.4–<3.4 | ≥3.4 | ||
| Cases/controls | 27/53 | 25/54 | 27/50 | . | 17/40 | 20/29 | 12/27 | |
| OR (95% CI) all | 1.00 | 0.93 (0.48, 1.82) | 1.10 (0.50, 2.41) | 0.61 | 1.00 | 1.62 (0.67, 3.89) | 1.09 (0.40, 3.01) | 0.25 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.86 (0.41, 1.77) | 0.96 (0.40, 2.35) | 0.31 | 1.00 | 1.92 (0.68, 5.45) | 1.18 (0.36, 3.83) | 0.21 |
| IL-5, pg/mL | <0.4 | 0.4–<0.9 | ≥0.9 | <0.4 | 0.4–<0.9 | ≥0.9 | ||
| Cases/controls | 18/50 | 30/51 | 31/56 | . | 17/43 | 16/27 | 16/26 | |
| OR (95% CI) all | 1 | 1.84 (0.85, 3.99) | 1.79 (0.80, 4.01) | 0.92 | 1 | 1.67 (0.71, 3.92) | 2.12 (0.73, 6.13) | 0.05 |
| OR (95% CI) >1 y onlyc | 1 | 2.12 (0.88, 5.12) | 2.17 (0.88, 5.32) | 0.86 | 1 | 1.49 (0.52, 4.26) | 1.45 (0.36, 5.80) | 0.15 |
| IL-6, pg/mL | <1.1 | 1.1–<2.7 | ≥2.7 | <1.1 | 1.1–<2.7 | ≥2.7 | ||
| Cases/controls | 25/54 | 28/55 | 26/48 | . | 14/40 | 19/33 | 16/23 | |
| OR (95% CI) all | 1.00 | 1.13 (0.58, 2.20) | 1.20 (0.58, 2.48) | 0.73 | 1.00 | 1.71 (0.72, 4.07) | 2.05 (0.81, 5.13) | 0.04 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.17 (0.57, 2.42) | 0.82 (0.35, 1.94) | 0.54 | 1.00 | 1.26 (0.44, 3.57) | 2.42 (0.75, 7.80) | 0.24 |
| IL-8, pg/mL | <6.7 | 6.7–<14.6 | ≥14.6 | <6.7 | 6.7–<14.6 | ≥14.6 | ||
| Cases/controls | 20/41 | 29/63 | 30/53 | . | 16/41 | 16/27 | 17/28 | |
| OR (95% CI) all | 1.00 | 0.93 (0.45, 1.93) | 1.15 (0.56, 2.36) | 0.40 | 1.00 | 1.61 (0.65, 3.95) | 1.70 (0.66, 4.35) | 0.13 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.96 (0.45, 2.07) | 1.04 (0.48, 2.26) | 0.62 | 1.00 | 1.70 (0.56, 5.20) | 2.92 (0.83, | 0.13 |
| IL-10, pg/mL | <0.6 | 0.6–<1.6 | ≥1.6 | <0.6 | 0.6–<1.6 | ≥1.6 | ||
| Cases/controls | 24/56 | 20/58 | 35/43 | . | 9/46 | 14/29 | 26/21 | |
| OR (95% CI) all | 1.00 | 0.80 (0.39, 1.66) | 2.36 (1.10, 5.05) | 0.06 | 1.00 | 4.15 (1.22, | 8.46 (2.71, | 0.01 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.61 (0.28, 1.33) | 1.62 (0.71, 3.69) | 0.64 | 1.00 | 5.11 (1.23, | 7.44 (1.97, | 0.12 |
| TNF-α, pg/mL | <1.7 | 1.7–<4.6 | ≥4.6 | <1.7 | 1.7–<4.6 | ≥4.6 | ||
| Cases/controls | 32/42 | 23/66 | 24/49 | . | 17/35 | 15/27 | 17/34 | |
| OR (95% CI) all | 1.00 | 0.42 (0.21, 0.85) | 0.58 (0.28, 1.22) | 0.92 | 1.00 | 1.16 (0.46, 2.92) | 1.03 (0.41, 2.61) | 0.28 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.40 (0.19, 0.84) | 0.68 (0.31, 1.51) | 0.68 | 1.00 | 1.09 (0.36, 3.29) | 0.85 (0.28, 2.56) | 0.31 |
| CRP, mg/L | <1.0 | 1.1–<3.1 | ≥3.1 | <1.0 | 1.1–<3.1 | ≥3.1 | ||
| Cases/controls | 30/54 | 22/52 | 27/51 | . | 16/32 | 17/32 | 16/32 | |
| OR (95% CI) all | 1.00 | 0.78 (0.41, 1.50) | 0.97 (0.49, 1.92) | 0.26 | 1.00 | 1.03 (0.43, 2.47) | 0.96 (0.38, 2.43) | 0.64 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.54 (0.26, 1.13) | 0.64 (0.30, 1.40) | 0.78 | 1.00 | 0.97 (0.31, 3.01) | 0.85 (0.26, 2.74) | 0.84 |
| Summary measured | <−0.5 | −0.5–<0.1 | ≥0.1 | <−0.5 | −0.5–<0.1 | ≥0.1 | ||
| Cases/controls | 24/53 | 28/54 | 27/50 | . | 20/42 | 14/25 | 15/29 | |
| OR (95% CI) all | 1.00 | 1.15 (0.59, 2.25) | 1.23 (0.60, 2.50) | 0.60 | 1.00 | 1.22 (0.51, 2.92) | 1.09 (0.45, 2.62) | 0.10 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.78 (0.38, 1.59) | 1.04 (0.46, 2.33) | 0.95 | 1.00 | 1.11 (0.37, 3.28) | 1.04 (0.36, 3.01) | 0.17 |
Abbrev: DLBCL, diffuse large B-cell lymphoma; BMI, body mass index; CRP, C-reactive protein IFN, Interferon; IL, Interleukin; TNF, Tumor neurosis factor.
a
OR and 95% CI estimated by conditional logistic regression; cases and controls matched on sex, birthdate (± 1 year), ethnicity, location (California or Hawaii), date of blood draw (within ±1 year), time of day of blood draw, and fasting hours prior to blood draw (0–<6, 6–<8, 8–<10, or ≥10).
b
prend based on the Wald χ2 test of a log-transformed continuous variable.
c
N=198 (66 cases and 132 controls) for DLBCL and N=97 (33 cases and 64 controls) for follicular lymphoma
d
Composite score from principal components analysis of log-transformed IL-1β, IL-4, IL-5, IL-6, IL-8, and TNF-α.